These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 18684697)

  • 1. Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery.
    Cacheux W; Boisserie T; Staudacher L; Vignaux O; Dousset B; Soubrane O; Terris B; Mateus C; Chaussade S; Goldwasser F
    Ann Oncol; 2008 Sep; 19(9):1659-61. PubMed ID: 18684697
    [No Abstract]   [Full Text] [Related]  

  • 2. Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
    Sogabe S; Komatsu Y; Yuki S; Kusumi T; Hatanaka K; Nakamura M; Kato T; Miyagishima T; Hosokawa A; Iwanaga I; Sakata Y; Asaka M
    Jpn J Clin Oncol; 2011 Apr; 41(4):490-7. PubMed ID: 21303790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma.
    Duffy A; Shia J; Huitzil-Melendez FD; Fong Y; O'Reilly EM
    Clin Colorectal Cancer; 2008 Mar; 7(2):140-3. PubMed ID: 18501074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases.
    Kesmodel SB; Ellis LM; Lin E; Chang GJ; Abdalla EK; Kopetz S; Vauthey JN; Rodriguez-Bigas MA; Curley SA; Feig BW
    J Clin Oncol; 2008 Nov; 26(32):5254-60. PubMed ID: 18854565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant therapy with bevacizumab.
    Gruenberger T; Gruenberger B; Scheithauer W
    J Clin Oncol; 2006 Jun; 24(16):2592-3; author reply 2593-4. PubMed ID: 16735714
    [No Abstract]   [Full Text] [Related]  

  • 6. [A case of pathological complete response of metachronous multiple liver metastases from colorectal cancer after mFOLFOX+bevacizumab chemotherapy].
    Otsuka S; Inagaki M; Nishie M; Hamano R; Tokunaga N; Takahashi K; Tsunemitsu Y; Miyoshi K; Iwakawa K; Takahashi M; Iwagak H
    Gan To Kagaku Ryoho; 2009 Nov; 36(12):2166-8. PubMed ID: 20037358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of 10 min infusion of bevacizumab in combination with 5FU-based chemotherapy in non-selected metastatic colorectal cancer patients.
    Coriat R; Mir O; Chaussade S; Goldwasser F
    Dig Liver Dis; 2011 Mar; 43(3):248-9. PubMed ID: 21145299
    [No Abstract]   [Full Text] [Related]  

  • 8. Aneurysm formation in an angiomyolipoma during bevacizumab combination therapy.
    Maleux G; Vaninbroukx J; Heye S; van Cutsem E; Oyen R
    Acta Oncol; 2010 Aug; 49(6):864-6. PubMed ID: 20230212
    [No Abstract]   [Full Text] [Related]  

  • 9. Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.
    Dohn LH; Jensen BV; Larsen FO
    Acta Oncol; 2010 Apr; 49(3):395-6. PubMed ID: 20001495
    [No Abstract]   [Full Text] [Related]  

  • 10. Correlation between response to chemotherapy with concomitant bevacizumab for hepatic metastasis of colorectal cancer and degree of enhancement using contrast-enhanced computed tomography.
    Osawa G; Yoshimatsu K; Yokomizo H; Okayama S; Sagawa M; Naritaka Y
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):209-15. PubMed ID: 23670642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Bevacizumab in the treatment of colorectal carcinoma: news from ASCO 2008].
    Mansueto G; Longo F
    Tumori; 2008; 94(4):suppl 1-14. PubMed ID: 18822711
    [No Abstract]   [Full Text] [Related]  

  • 12. Management of colorectal liver metastases after complete response to neoadjuvant chemotherapy. A case of computertomography-guided wire marking of the liver tumor.
    Kornprat P; Schöllnast H; Cerwenka H; Werkgartner G; Bernhardt G; Mischinger HJ
    Int J Colorectal Dis; 2009 Jan; 24(1):125-6. PubMed ID: 18682963
    [No Abstract]   [Full Text] [Related]  

  • 13. Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
    Stremitzer S; Stift J; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
    Eur J Surg Oncol; 2015 Jul; 41(7):868-74. PubMed ID: 25865557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.
    Schwartzberg LS; Rivera F; Karthaus M; Fasola G; Canon JL; Hecht JR; Yu H; Oliner KS; Go WY
    J Clin Oncol; 2014 Jul; 32(21):2240-7. PubMed ID: 24687833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent disease four years after surgery and adjuvant chemotherapy.
    Pozzo C; Barone C
    Cancer Treat Rev; 2008; 34 Suppl 2():S8-11. PubMed ID: 19101406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hepatic resection after systemic chemotherapy for liver metastasis of colorectal cancer].
    Nishigaki T; Ide Y; Murata K
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2566-8. PubMed ID: 21224641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New drugs for colorectal cancer].
    Pestalozzi BC; Jäger D; Knuth A
    Praxis (Bern 1994); 2004 Sep; 93(36):1455-9. PubMed ID: 15487860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Portal thrombosis and steatosis after preoperative chemotherapy with FOLFIRI-bevacizumab for colorectal liver metastases.
    Donadon M; Vauthey JN; Loyer EM; Charnsangavej C; Abdalla EK
    World J Gastroenterol; 2006 Oct; 12(40):6556-8. PubMed ID: 17072991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases.
    Maru DM; Kopetz S; Boonsirikamchai P; Agarwal A; Chun YS; Wang H; Abdalla EK; Kaur H; Charnsangavej C; Vauthey JN; Loyer EM
    Am J Surg Pathol; 2010 Sep; 34(9):1287-94. PubMed ID: 20697255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The development of the first line treatment of metastatic colorectal cancer (mCRC)].
    Landherr L; Nagykálnai T
    Magy Onkol; 2009 Sep; 53(3):237-46. PubMed ID: 19793687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.